Clinical trial
Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV…
NCT00003560 · Herbert Irving Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00003560 |
|---|---|
| Title | Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Official title | A Phase II Study of Docetaxel and Carboplatin for Suboptimally Debulked Stage III or Stage IV Ovarian and Fallopian Tube Carcinoma |
| Lead sponsor | Herbert Irving Comprehensive Cancer Center, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, docetaxel |
| Enrollment | 40 |
| Start date | May 1, 1998 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: